Intralesional Chemotherapy for Laryngeal Cancer

This trial tests the effects of injecting a chemotherapy drug directly into tumors for individuals with recurrent laryngeal cancer. The treatment combines cisplatin, a common chemotherapy drug, with epinephrine to enhance the drug's effects. Participants will receive three weekly doses before surgery. Candidates may qualify if their laryngeal cancer returned after radiation and they are prepared for chemotherapy injections and surgery. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group, providing an opportunity to contribute to important findings.

The trial does not specify if you need to stop taking your current medications, but you cannot be on any concurrent anticancer therapy. If you're taking steroids for allergies or other conditions, they are allowed if the dose is 10 mg/day or less.

Research has shown that injecting a mix of cisplatin and epinephrine directly into tumors may help treat laryngeal cancer. In studies using this combination, about 25% of tumors responded, with some even shrinking completely, suggesting the treatment could be effective.

Regarding safety, past studies found that cisplatin and epinephrine are generally well-tolerated. Patients experienced some side effects, but these were mostly manageable. Since this trial is in the middle phase, early safety results have been promising enough to warrant further studies. This suggests that while risks exist, researchers believe they are acceptable compared to the potential benefits.

Unlike the standard treatments for laryngeal cancer, which often include radiation therapy or systemic chemotherapy, this new approach uses intralesional chemotherapy with a combination of cisplatin and epinephrine. This treatment is unique because it is delivered directly into the tumor, potentially increasing drug concentration at the cancer site while minimizing side effects to the rest of the body. Researchers are excited about this method as it may enhance the effectiveness of chemotherapy and reduce the need for more invasive procedures. By combining cisplatin with epinephrine, the treatment could improve drug absorption and retention within the tumor, offering a novel way to tackle laryngeal cancer.

Participants in this trial will receive a combination of cisplatin and epinephrine injected directly into tumors. Research has shown that this combination can shrink tumors and improve symptoms. One study found that this mix effectively reduced tumor size, offering hope for treating laryngeal cancer. While cisplatin is a common cancer drug, adding epinephrine helps it remain longer at the tumor site, potentially enhancing its effectiveness. This approach has shown positive results in patients, suggesting it could be a viable option for those with recurring laryngeal cancer.²⁶⁷⁸⁹